Mutation analysis of the ryanodine receptor gene isoform 3 (RYR3) in recurrent neuroleptic malignant syndrome [15]

Journal of Clinical Psychopharmacology

Volumn 24, Issue 4, 2004, Pages 471-473

  Dettling, Michael ^a   Sander, Thomas ^a   Weber, Markus ^b   Steinlein, Ortrud K ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Institute of Legal Medicine of Schleswig Holstein   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENPERIDOL; CALCIUM ION; CHLORPROTHIXENE; CLOZAPINE; COMPLEMENTARY DNA; FLUPHENAZINE; FLURAZEPAM; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; RYANODINE RECEPTOR; THIORIDAZINE;

ADULT; CALCIUM TRANSPORT; CASE REPORT; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; FEMALE; GENE EXPRESSION; GENOME; HUMAN; LETTER; MALE; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; NUCLEOTIDE SEQUENCE; PARANOID SCHIZOPHRENIA; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECEPTOR GENE; RECURRENT DISEASE; RYR3 GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PROTEIN ISOFORMS; RECURRENCE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 3242667056     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000130559.93748.65     Document Type: Letter

References (13)

1. Gurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. 1992;53:56-62.
2. Mann SC, Caroff SN, Fricchione G, et al. Central dopamine hypoactivity and pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann. 2000;30:363-373.
3. Caroll BT. The Universal Field Hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectr. 2000;5:26-33.
4. Guerrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156:169-180.
5. Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol. 2002;25:183-193.
6. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry. 1996;39:1-13.
7. Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm. 2002;109:1453-1467.
8. Rossi D, Sorrentino V. Molecular genetics of ryanodine receptors Ca(2+)-release channels. Cell Calcium. 2002;32:307-319.
9. Myatake R, Iwahashi K, Matsushita M, et al. No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia. J Neurol Sci. 1996;143:161-165.
10. Sorrentino V, Giannini G, Malzac P, et al. Localization of a novel ryanodine receptor gene (RYR3) to human chromosome 15q14-q15 by in situ hybridization. Genomics. 1993;18:163-165.
11. Stober G, Saar K, Ruschendorf F, et al. Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet. 2000;67:1201-1207.
12. Freedman R, Coon H, Myles-Worsley M, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 1997;94:587-592.
13. Nakashima Y, Nishimura S, Maeda A, et al. Molecular cloning and characterization of a human brain ryanodine receptor. FEBS Lett. 1997;417:157-162.